Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Amag Pharmaceuticals Inc.
Headquarters: Waltham, MA, United States of America
Website: N/A
Year Founded: 1981
Status: Acquired
BioCentury | Mar 9, 2023
Regulation
Makena shows why FDA wants confirmatory trials started before accelerated approval
A firestorm over pricing, a failed confirmatory trial and more than $1.5B in sales mark preterm birth drug’s 12-year journey from accelerated approval
BioCentury | Feb 7, 2023
Management Tracks
Okamura to lead Astellas
Plus: Myers at the helm of Viridian, and updates from Novartis,
BioCentury | Jan 7, 2023
Management Tracks
Schulman named chair of Alnylam, Bertozzi joins board
Plus: Estigarribia becomes InterVenn CEO and updates from Lyndra, Catalio, Pneumagen and more
BioCentury | Jan 4, 2023
Management Tracks
Ex-Checkmate CEO Bash to lead ZielBio
Plus: Allogene’s Amado joins Zai Lab, and updates from bluebird bio, Rejuvenate, Novadip and more
BioCentury | Apr 28, 2022
Management Tracks
Merck’s Garay to head commercial at Moderna
Plus Turtle leaving BridgeBio, and updates from Clover, Y-mAbs, Genenta and more
BioCentury | Mar 11, 2022
Emerging Company Profile
Adiso debuts with inflammatory pipeline, $60M from Morningside
Company seeking syndicate for series B
BioCentury | Oct 22, 2021
Management Tracks
New board chairman at Dynavax
Plus: Arcturus, BioDelivery, Landmark Bio, Vitrolife, Novome and more
BioCentury | Aug 23, 2021
Regulation
Makena returning to spotlight as FDA allows hearing
Preterm birth drug has long been focus of drug pricing, efficacy concerns
BioCentury | Feb 9, 2021
Management Tracks
Dynavax taps Yu to head vaccine research; plus CFO moves at Lilly, Gemini, Caribou and Lyell
Dong Yu joined vaccine developer Dynavax Technologies Corp. (NASDAQ:DVAX) as SVP of vaccine research. Yu was previously head of preclinical R&D U.S. at GlaxoSmithKline plc (LSE:GSK;
BioCentury | Oct 15, 2020
Product Development
Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation
Updates on Russia’s latest COVID-19 vaccine approval and more
Items per page:
1 - 10 of 265